» Articles » PMID: 16126327

Photoselective Vaporization (PVP) Versus Transurethral Resection of the Prostate (TURP): a Prospective Bi-centre Study of Perioperative Morbidity and Early Functional Outcome

Overview
Journal Eur Urol
Specialty Urology
Date 2005 Aug 30
PMID 16126327
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To compare the early follow-up and perioperative morbidity of photoselective vaporization (PVP) and transurethral resection of the prostate (TURP) in patients (pts.) suffering from lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

Material And Method: 101 pts. underwent PVP (n = 64) and TURP (n = 37) in a prospective, non-randomized bi-centre trial. Inclusion criteria were identical at both centres. Primary outcome parameters were maximum urinary flow rate (Q(max)), post-void residual volume (V(res)), International Prostate Symptom Score (IPSS). Secondary outcomes included intraoperative surgical parameters and perioperative and post-discharge morbidity.

Results: Baseline characteristics of both groups were similar. Operating time was slightly shorter in the TURP group (p = 0.047). During TURP significant more irrigation solution was used (p < 0.001). Decrease of serum haemoglobin (p = 0.027) and serum sodium (p = 0.013) was larger after TURP. Catheter drainage was removed significant earlier after PVP than after TURP (p < 0.001). Outcome of Q(max), and IPSS were similar in both groups within 6 months. The sort of perioperative complications was different in both groups, however overall cumulative perioperative morbidity was comparable (PVP 39.1% versus TURP 43.2.1%; ns).

Conclusion: PVP provides excellent intraoperative safety, instant tissue removal, and immediate relief from obstructive voiding symptoms, similar to TURP. Early outcomes 6-months after PVP and TURP are comparable.

Citing Articles

Efficacy and safety of Vibegron for the treatment of residual overactive bladder symptoms after laser vaporization of the prostate: A single-center prospective randomized controlled trial (VAPOR TRIAL).

Seki N, Masaoka H, Song Y, Dejima T, Sato Y, Maeda S Low Urin Tract Symptoms. 2024; 16(4):e12529.

PMID: 38956950 PMC: 11500685. DOI: 10.1111/luts.12529.


Treating LUTS in Men with Benign Prostatic Obstruction: A Review Article.

Murad L, Bouhadana D, Nguyen D, Chughtai B, Zorn K, Bhojani N Drugs Aging. 2023; 40(9):815-836.

PMID: 37556075 DOI: 10.1007/s40266-023-01054-0.


A systematic review and meta-analysis of efficacy and safety comparing greenlight laser vaporization with transurethral resection of the prostate for benign prostatic hyperplasia with prostate volume less than 80 ml.

Liu S, Liu H, Yao H, Sun F, Wu J, Zhou Z Lasers Med Sci. 2023; 38(1):133.

PMID: 37289405 DOI: 10.1007/s10103-023-03794-2.


Short- and long-term risks of photoselective laser vaporization of the prostate: a population-based comparison with transurethral resection of the prostate.

Salmivalli A, Ettala O, Nurminen P, Kinnala P, Bostrom P, Kyto V Ann Med. 2023; 55(1):1287-1294.

PMID: 36974584 PMC: 10054157. DOI: 10.1080/07853890.2023.2192046.


UPDATE - Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia.

Elterman D, Aube-Peterkin M, Evans H, Elmansy H, Meskawi M, Zorn K Can Urol Assoc J. 2022; 16(8):245-256.

PMID: 35905485 PMC: 9343161. DOI: 10.5489/cuaj.7906.